Manufacturing and Production

Showing 15 posts of 5857 posts found.

landing-hero-images1

ViiV’s HIV drug Rukobia gets EC marketing authorisation

February 9, 2021 Manufacturing and Production HIV, ViiV

The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …
spravato

Janssen’s esketamine nasal spray gets Europe approval for new indication

February 9, 2021 Manufacturing and Production Europe, Janssen

The European Commission (EC) has authorised the expanded use of Janssen’s Spravato (esketamine nasal spray), co-administered with oral antidepressant therapy in …
mark_wilcox_002

Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board

February 4, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening …
caroline_oconnor

Raremark appoints Caroline O’Connor as CCO

February 4, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer. Previously holding the position of Raremark’s Senior Vice President …
philippe_dro

Scenic Biotech appoints Dr Philippe Dro as Chairman

February 2, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Scenic Biotech has announced the appointment of Dr Philippe Dro as its independent Chairman. Dr Dro replaces Dr Ulrich Grau, …

Chelsea & Westminster Hospital launches diabetes care app

February 2, 2021 Manufacturing and Production

Chelsea and Westminster Hospital NHS Foundation Trust have today announced the use of a new app designed to revolutionise diabetes …
dw-anzcxqaqavhl

FDA approves new IM administration route for Biogen’s MS drug Plegridy

February 2, 2021 Manufacturing and Production Biogen, MS

The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …
merckincweb

Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds

February 2, 2021 Manufacturing and Production Cancer, MSD

A new trial by Merck – known as MSD outside of North America – has found that their lung cancer …

EMA recommends Arvelle’s seizure drug cenobamate

February 2, 2021 Manufacturing and Production Arvelle Therapeutics, epilepsy

The EMA has recommended the approval of Arvelle Therapeutics’ cenobamate for the adjunctive treatment of focal onset seizures with or …
gocovri

Adamas’ Parkinson’s drug gets US marketing authorisation for second indication

February 2, 2021 Manufacturing and Production Adamas Pharmaceuticals, FDA

The FDA has granted marketing authorisation for a second indication for Adamas Pharmaceuticals’ Gocovri (amantadine) extended release capsules. The drug …
european_commission_web

MSD’s cancer therapy KEYTRUDA gets EU approval

January 26, 2021 Manufacturing and Production Cancer, MSD

MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …
fdaoutsideweb

FDA approves Aurinia’s oral lupus nephritis therapy

January 26, 2021 Manufacturing and Production Aurinia

The FDA has approved Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients …
astrazeneca_building_white

AstraZeneca rejects “incorrect” claims about COVID-19 vaccine efficacy

January 26, 2021 Manufacturing and Production AstraZeneca, COVID-19

AstraZeneca has rejected claims by German media that its COVID-19 vaccine has only 8% efficacy in over-65s. Two German newspapers, …
merckincweb

MSD discontinues development of COVID-19 vaccines

January 26, 2021 Manufacturing and Production MSD, Merck

Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …
abbvie_0

AbbVie’s psoriatic arthritis and ankylosing spondylitis drug gets EU approval

January 26, 2021 Manufacturing and Production AbbVie

The European Commission (EC) has approved AbbVie’s RINVOQTM (upadacitinib 15 mg), an oral, once-daily selective and reversible JAK inhibitor for …
The Gateway to Local Adoption Series

Latest content